24 filings · most recent first
UTHR 8-K Filings
Shareholders Approve United Therapeutics 2026 Stock Incentive Plan
United Therapeutics Reports Q1 2026 Financial Results
United Therapeutics Announces Positive Teton1 Study Results For Tyvaso In Ipf
United Therapeutics Announces 2 Billion Stock Repurchase Program
United Therapeutics Announces Positive Ralinepag Results In Pah Clinical Trial
United Therapeutics Appoints Dr Kevin J Tracey To Board Of Directors
United Therapeutics Reports Record Revenues And Net Income For 2025
United Therapeutics Reports Record Q2 2025 Financial Results And Authorizes 1B
United Therapeutics Announces Positive Results For Tyvaso In Treating Ipf
United Therapeutics Announces 1 Billion Share Repurchase Program
United Therapeutics Corporation Shareholders Approve Stock Incentive Plan
United Therapeutics Enters Into New Credit Agreement And Terminates Previous One
United Therapeutics Presents Business Update At Jp Morgan Healthcare Conference
United Therapeutics Elects Jan Malcolm To Board Restates Stock Plan
United Therapeutics Extends Credit Agreement Maturity Date By One Year
United Therapeutics Authorizes 1 Billion Share Repurchase Program
United Therapeutics Files For Preliminary Injunction In Patent Litigation
United Therapeutics Announces Record Third Quarter 2025 Financial Results
United Therapeutics Reports Strong Q1 2025 Financial Results
United Therapeutics Reports Record 2024 Revenues And Net Income
United Therapeutics Announces Strong Third Quarter 2024 Financial Results
United Therapeutics Announces 20 Yearoveryear Revenue Growth For Q2 2024
United Therapeutics Reports 34 Yoy Revenue Growth And Announces 1B Share
United Therapeutics Announces Record Q4 And Fullyear 2023 Revenues And Files